Moré RJC, Hernández BD, Santo NY

Language: Spanish
References: 8
Page: 66-70
PDF size: 164.87 Kb.

ABSTRACT

Introduction: diffuse B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults. It is characterized by its aggressiveness and wide location. Usually, the first sign of its presence is a rapidly growing mass, with some lymph nodes. Fever, weight loss and profuse night sweats may also occur.
Objective: a case of diffuse large B-cell lymphoma is presented which by its atypical presentation form (soft-tissue lymphoma with internal organs), is of interest to the specialists.
Case presentation: female patient, 65 years old, dark skin color and a history of arterial hypertension. She came to the clinic for presenting a painful tumor mass in the left region of the back and weight loss. Did not present cough, dyspnea or other respiratory symptoms. During the physical examination, a hard, non-painful and immovable mass of approximately 12 x 12 cm was palpated on the left posterolateral thoracic wall. In the immunohistochemical examination the presence of diffuse large B-cell lymphoma (stage IV) was confirmed.
Discussion: despite the atypical presentation of the disease, the immunohistochemical diagnosis and the involvement of other organs (ribs and pleura) are data consistent with what has been reported in the literature.
Conclusions: in the presence of a painful tumor mass and weight loss without other symptoms, diffuse large B-cell lymphoma with atypical presentation should be considered as possible diagnosis.

REFERENCES

1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer [Internet]. Nov 2011 [citado 12 Mar 2015];105(11):1684-92. Disponible en: https://www.nature.com/bjc/journal/v105/n11/pdf/bjc2011450a.pdf

2. Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol [Internet]. Dic 2009 [citado 12 Mar 2015];148(5):739- 53. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.08010.x/epdf

3. Goldman L, Schafer AI. Cecil. Tratado de Medicina Interna. 24ta ed. Madrid: Elsevier España; 2012.

4. Basquiera A, Márquez M, Vijnovich A, Picon A, Zerga M. Linfoma difuso de células grandes B. SAH [Internet]. 2012 [citado 9 Dic 2016];2019(26):251-74. Disponible en: http://sah.org.ar/docs/251-274.5B.SAH_GUIA2012_LinfomaCelulasGrandes_1.pdf

5. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med [Internet]. Abr 2010 [citado 12 Mar 2015];362(15):1417-29. Disponible en: http://xa.yimg.com/kq/groups/24808814/1612002958/name/Aggressive+Lymphomas.pdf

6. Farber CM, Axelrod RC. The clinical and economic value of Rituximab for the treatment of hematologic malignancies. Contemp Oncol [Internet]. Mar 2011 [citado 12 Mar 2016];3(1):[aprox. 9 p.]. Disponible en: http://www.onclive.com/publications/contemporaryoncology/ 2011/spring-2011/the-clinical-and-economic-value-of-rituximab-for-the-treatmentof- hematologic-malignancies

7. Armitage JO. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc [Internet]. Feb 2012 [citado 12 Mar 2016];87(2):161-71. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497705/pdf/main.pdf

8. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin′s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. May 2010 [citado 12 Mar 2016];21(Supl 5):v172-4. Disponible en: http://www.alabmed.com/uploadfile/2013/1218/20131218093226913.pdf